FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2536618980> ?p ?o ?g. }

• W2536618980 endingPage "5786" @default.
• W2536618980 startingPage "5786" @default.
• W2536618980 abstract "Abstract Background Side population (SP) cells are known as enriched source of cancer initiating cells with stem cell properties. The SP cells show a distinct low-staining pattern with the Hoechst 33342 dye. Our aim was to identify SP cells in multiple myeloma (MM) cell lines as well as characteristics of SP cells. Furthermore, we investigated drugs that are effective against SP cells of MM. Methods SP (side population), MP (main population) cells from human multiple myeloma cell line (RPMI8226) were sorted by flow cytometry based Hoechst 33342 staining. We performed proliferative capacity in vitro, colony-forming cell assay, cell cycle analysis, drug toxicity (doxorubicin, dexamethasone, bortezomib, melphalan). Expression of stem cell markers (ABCG2, Oct4, Sox2, and Nanog) was observed by western blotting assay. Results Several established studies have shown a clonogenic MM cell population with CD 138-status. Therefore, we assessed whether there is correlation between CD 138 - subpopulations and SP cells. CD 138- subpopulations of MM cell lines were not consistent with SP cells. And we have found no correlation between expression of CD 19, CD20, and CD 27 and the proportion of SP cells. No difference was observed for expression of stem cell marker between the SP cells and MP cells. We examined cell cycle analysis and proliferation ability of SP and MP cells. SP cells showed a capacity for higher proliferation abilities and clonogenecity than MP cells. (Fig1,2) We investigated target SP cells with several drugs (doxorubicin, dexamethasone, melphalan, bortezomib). Importantly, bortezomib was the most effective drug for SP cells.(Table1) Conclusion In our study, there was lack of evidence that SP cells was consistent with MM stem cells. No difference was observed for any other marker between SP cells and MP cells. However SP cells had higher proliferation index and clonogenicity compared with MP cells. We suggest that SP cells are rather related to resistance of drugs. Furthermore, bortezomib reduced the SP cells more effectively compared to other drugs. Fig 1. Colony assay Fig 1. Colony assay Fig 2. Cell growth ( X 105 ) Fig 2. Cell growth ( X 105 ) Disclosures No relevant conflicts of interest to declare." @default.
• W2536618980 created "2016-10-28" @default.
• W2536618980 creator A5004951763 @default.
• W2536618980 creator A5012507797 @default.
• W2536618980 creator A5023107984 @default.
• W2536618980 creator A5025416763 @default.
• W2536618980 creator A5034534274 @default.
• W2536618980 creator A5035019823 @default.
• W2536618980 creator A5036071367 @default.
• W2536618980 creator A5044444009 @default.
• W2536618980 creator A5047621773 @default.
• W2536618980 creator A5058412527 @default.
• W2536618980 creator A5060654871 @default.
• W2536618980 creator A5066261268 @default.
• W2536618980 creator A5067436403 @default.
• W2536618980 creator A5071881182 @default.
• W2536618980 creator A5073384154 @default.
• W2536618980 creator A5083760245 @default.
• W2536618980 creator A5085596906 @default.
• W2536618980 date "2014-12-06" @default.
• W2536618980 modified "2023-09-27" @default.
• W2536618980 title "Side Population of Multiple Myeloma and Multiple Myeloma Stem Cell" @default.
• W2536618980 doi "https://doi.org/10.1182/blood.v124.21.5786.5786" @default.
• W2536618980 hasPublicationYear "2014" @default.
• W2536618980 type Work @default.
• W2536618980 sameAs 2536618980 @default.
• W2536618980 citedByCount "2" @default.
• W2536618980 countsByYear W25366189802015 @default.
• W2536618980 countsByYear W25366189802017 @default.
• W2536618980 crossrefType "journal-article" @default.
• W2536618980 hasAuthorship W2536618980A5004951763 @default.
• W2536618980 hasAuthorship W2536618980A5012507797 @default.
• W2536618980 hasAuthorship W2536618980A5023107984 @default.
• W2536618980 hasAuthorship W2536618980A5025416763 @default.
• W2536618980 hasAuthorship W2536618980A5034534274 @default.
• W2536618980 hasAuthorship W2536618980A5035019823 @default.
• W2536618980 hasAuthorship W2536618980A5036071367 @default.
• W2536618980 hasAuthorship W2536618980A5044444009 @default.
• W2536618980 hasAuthorship W2536618980A5047621773 @default.
• W2536618980 hasAuthorship W2536618980A5058412527 @default.
• W2536618980 hasAuthorship W2536618980A5060654871 @default.
• W2536618980 hasAuthorship W2536618980A5066261268 @default.
• W2536618980 hasAuthorship W2536618980A5067436403 @default.
• W2536618980 hasAuthorship W2536618980A5071881182 @default.
• W2536618980 hasAuthorship W2536618980A5073384154 @default.
• W2536618980 hasAuthorship W2536618980A5083760245 @default.
• W2536618980 hasAuthorship W2536618980A5085596906 @default.
• W2536618980 hasBestOaLocation W25366189801 @default.
• W2536618980 hasConcept C104317684 @default.
• W2536618980 hasConcept C107459253 @default.
• W2536618980 hasConcept C117262875 @default.
• W2536618980 hasConcept C136302470 @default.
• W2536618980 hasConcept C145103041 @default.
• W2536618980 hasConcept C1491633281 @default.
• W2536618980 hasConcept C153911025 @default.
• W2536618980 hasConcept C203014093 @default.
• W2536618980 hasConcept C207701140 @default.
• W2536618980 hasConcept C2776364478 @default.
• W2536618980 hasConcept C2777478702 @default.
• W2536618980 hasConcept C2777933648 @default.
• W2536618980 hasConcept C2780546549 @default.
• W2536618980 hasConcept C2780932548 @default.
• W2536618980 hasConcept C28328180 @default.
• W2536618980 hasConcept C2908647359 @default.
• W2536618980 hasConcept C502942594 @default.
• W2536618980 hasConcept C54355233 @default.
• W2536618980 hasConcept C553184892 @default.
• W2536618980 hasConcept C55427017 @default.
• W2536618980 hasConcept C55493867 @default.
• W2536618980 hasConcept C71924100 @default.
• W2536618980 hasConcept C81885089 @default.
• W2536618980 hasConcept C86803240 @default.
• W2536618980 hasConcept C95444343 @default.
• W2536618980 hasConcept C99454951 @default.
• W2536618980 hasConceptScore W2536618980C104317684 @default.
• W2536618980 hasConceptScore W2536618980C107459253 @default.
• W2536618980 hasConceptScore W2536618980C117262875 @default.
• W2536618980 hasConceptScore W2536618980C136302470 @default.
• W2536618980 hasConceptScore W2536618980C145103041 @default.
• W2536618980 hasConceptScore W2536618980C1491633281 @default.
• W2536618980 hasConceptScore W2536618980C153911025 @default.
• W2536618980 hasConceptScore W2536618980C203014093 @default.
• W2536618980 hasConceptScore W2536618980C207701140 @default.
• W2536618980 hasConceptScore W2536618980C2776364478 @default.
• W2536618980 hasConceptScore W2536618980C2777478702 @default.
• W2536618980 hasConceptScore W2536618980C2777933648 @default.
• W2536618980 hasConceptScore W2536618980C2780546549 @default.
• W2536618980 hasConceptScore W2536618980C2780932548 @default.
• W2536618980 hasConceptScore W2536618980C28328180 @default.
• W2536618980 hasConceptScore W2536618980C2908647359 @default.
• W2536618980 hasConceptScore W2536618980C502942594 @default.
• W2536618980 hasConceptScore W2536618980C54355233 @default.
• W2536618980 hasConceptScore W2536618980C553184892 @default.
• W2536618980 hasConceptScore W2536618980C55427017 @default.
• W2536618980 hasConceptScore W2536618980C55493867 @default.
• W2536618980 hasConceptScore W2536618980C71924100 @default.
• W2536618980 hasConceptScore W2536618980C81885089 @default.
• W2536618980 hasConceptScore W2536618980C86803240 @default.

• next